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Simple Summary: Cancers arising from the lining of the uterus, endometrial cancers, are the most 
common gynecologic malignancy in the United States. Once endometrial cancer escapes the uterus 
and grows in distant locations, there are limited therapeutic options. The most aggressive and lethal 
endometrial cancers carry alterations in the protein p53, which is a critical guardian of many cellular 
functions. The role of these p53 alterations in endometrial cancer is not well understood. The goal 
of this work was to use p53 altered models of endometrial cancer to understand which, if any, ther-
apeutically targetable vulnerabilities these p53 alterations may confer in endometrial cancer. Here 
we show that many of these p53 altered cells have problems with cell division, which can be tar-
geted with novel single and combination therapies. These discoveries may lead to relevant new 
therapies for difficult to treat advanced stage endometrial cancers. 
Abstract: Uterine carcinoma (UC) is the most common gynecologic malignancy in the United States. 
TP53 mutant UCs cause a disproportionate number of deaths due to limited therapies for these 
tumors and the lack of mechanistic understanding of their fundamental vulnerabilities. Here we 
sought to understand the functional and therapeutic relevance of TP53 mutations in UC. We func-
tionally profiled targetable TP53 dependent DNA damage repair and cell cycle control pathways in 
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a panel of TP53 mutant UC cell lines and patient-derived organoids. There were no consistent de-
fects in DNA damage repair pathways. Rather, most models demonstrated dependence on defective 
G2/M cell cycle checkpoints and subsequent upregulation of Aurora kinase-LKB1-p53-AKT signal-
ing in the setting of baseline mitotic defects. This combination makes them sensitive to Aurora ki-
nase inhibition. Resistant lines demonstrated an intact G2/M checkpoint, and combining Aurora 
kinase and WEE1 inhibitors, which then push these cells through mitosis with Aurora kinase inhib-
itor-induced spindle defects, led to apoptosis in these cases. Overall, this work presents Aurora ki-
nase inhibitors alone or in combination with WEE1 inhibitors as relevant mechanism driven thera-
pies for TP53 mutant UCs. Context specific functional assessment of the G2/M checkpoint may serve 
as a biomarker in identifying Aurora kinase inhibitor sensitive tumors. 
Keywords: Aurora kinase; LKB1; uterine cancer; p53; G2/M cell cycle checkpoint 
 
1. Introduction 
Uterine carcinoma (UC) is the most common gynecologic malignancy in the United 
States with high-grade endometrioid and serous subtypes, which are typically TP53 mu-
tant, being the most lethal and difficult to treat [1,2]. Once these tumors spread beyond 
the uterus, limited therapeutic options exist, largely due to our minimal understanding of 
the major mechanistic defects and drivers of this disease [3]. Genomic sequencing reveals 
somatic mutations in only a few genes segregating UCs into well-defined molecular sub-
sets [4]. However, beyond genetic alterations in the mismatch repair pathway or POLE 
gene potentially increasing immunotherapy sensitivity [5], few targetable genetic altera-
tions exist across UC subtypes [4]. 
TP53 mutations are one of the most common genomic alterations across all high-
grade UC subtypes and associate with higher mortality; however, the functional and ther-
apeutic relevance of these alterations remains ambiguous [4,6]. p53 has been widely stud-
ied across every malignancy and has many functions during cellular stress, including cell 
cycle arrest or apoptosis after DNA damage [7–9]. However, DNA damage repair (DDR) 
capacity and cell cycle checkpoint integrity across TP53 mutant uterine tumors has not 
been fully characterized. 
Of interest are current clinical trials with DDR agents in recurrent UCs [10–12]. In 
one recent clinical trial, a subset of uterine serous tumor patients demonstrated response 
to the WEE1 inhibitor AZD1775 [13]. AZD1775 can both alter the cell cycle and destabilize 
replication forks causing DNA damage [14–17]. It is unclear from this trial whether the 
functional defect in responsive patients was in cell cycle control or replication fork stabil-
ity [13]. Indeed, many TP53 mutant tumors harbor mutations in oncogenes such as MYC, 
which might contribute to oncogene-driven replication stress [4], while others harbor mu-
tations or copy number alterations in genes with cell cycle regulatory functions such as 
LKB1 (STK11) or AURKA, which combined with a TP53 mutation may alter cell cycle 
checkpoints [18,19]. 
Thus, we sought to elucidate the functional and therapeutic relevance of TP53 muta-
tions in UCs, especially in the capacity of these tumors to repair DNA damage and control 
cell cycle checkpoints. We demonstrate that most of these tumors lack innate defects in 
the homologous recombination (HR) and stalled replication fork protection DDR path-
ways; rather, they harbor innate mitotic progression or spindle defects. This makes them 
heavily dependent on both defective G2/M checkpoints and upregulated Aurora kinase–
LKB1–p53–AKT signaling for survival, increasing sensitivity to the Aurora kinase inhibi-
tor Alisertib. For Alisertib resistant cells, addition of a WEE1 kinase inhibitor promotes 
mitotic progression after Alisertib induced mitotic alterations, leading to cell death. Our 
data indicate that Aurora kinase inhibitors alone or in combination with WEE1 inhibitors 
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may offer unique mechanism driven targeted therapies for patients with G2/M checkpoint 
deficient TP53 mutant UCs. 
2. Materials and Methods 
For additional Materials and Methods, please see Supplementary Materials and 
Methods. 
2.1. TP53 Sequencing 
gDNA was prepared from cell lines using Qiagen’s DNeasy Blood and Tissue kit 
(Cat. #69504). gDNA was analyzed using Genewiz’s TP53 Sanger sequencing pipeline for 
exons 1–10 of the TP53 gene. These results were used to validate publicly available TP53 
mutation status for these cell lines [20–23]. 
2.2. Next Generation Sequencing of Organoids 
gDNA was generated from all six organoid models and parent tumors using Qi-
agen’s DNeasy Blood and Tissue kit and submitted to the Center for Patient-Derived Mod-
els at Dana-Farber Cancer Institute. To validate the parent tumors and organoids as com-
ing from the same patient, all six pairs underwent STR profiling and proved to be exact 
matches. The organoids underwent copy number and somatic mutation analysis using 
low pass-whole genome sequencing and targeted exome sequencing (ModelSeq panel). 
2.3. Bulk RNA Sequencing 
Organoids were treated with either vehicle or 1 uM AZD1775. After 14 hours, the 
organoids were scraped from the plate, washed in PBS, Matrigel extracted in Corning’s 
Cell Recovery Solution (Cat. #354253), washed in PBS, and snap frozen. RNA was ex-
tracted using Qiagen’s RNeasy kit (Cat. # 74104) with on-column DNAse digest (Qiagen 
Cat. #79254). Total RNA was sequenced using Novogene’s standard Illumina RNAseq 
platform. VIPER was used for sequencing cleanup and differential expression analysis 
[24]. GO overrepresentation analysis was performed for significantly upregulated genes 
using clusterProfiler (logFC > 0, adj. p value < 0.05) [25]. 
2.4. Accession Number 
The sequencing data discussed in this study have been deposited in the Gene Expres-
sion Omnibus (GEO) database and are accessible through GEO Series accession number 
GSE171516. 
3. Results 
3.1. Functional Testing of DDR Pathways in a Panel of TP53 Mutant UC Models Reveals No 
Significant Defects 
Since p53 is a master regulator of the cell cycle and survival amid DNA damage, we 
asked whether high-grade TP53 mutant UCs harbor defects in DDR increasing suscepti-
bility to DDR targeted therapies [7–9], which target defects in repair of double strand 
DNA breaks (DSB) by HR and protection of stalled replication forks [26]. Functional as-
says for HR defects include (1) assessing tumor cell formation of post-damage RAD51 
nuclear foci, and (2) challenging cells with DSB inducing agents such as gamma irradia-
tion, PARP inhibitors, and platinum crosslinking agents [27]. Cells with intact HR capacity 
form foci and are resistant to DSB inducing agents. Functional assays for stalled replica-
tion fork protection include (1) DNA fiber assays, and (2) challenging cells with agents 
that stall replication forks such as gemcitabine, ATR inhibitors, or WEE1 inhibitors [27,28]. 
To functionally assess these pathways in TP53-mutant UCs, we compiled a panel of 
TP53-mutant UC cell lines and established multiple patient-derived organoids (PDOs) 
(Figures 1A–C and S1A,B) [20]. Models were of endometrioid and serous histologies, and 
organoid sites of origin included both primary hysterectomies and solid or ascites 
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recurrences (Figures 1A and S1A). TP53 mutations were validated using Sanger or next-
generation sequencing in cell lines and organoids, respectively (Figures 1A,B) [20–23]. The 
somatic mutation and copy number profile of the organoids was established using next-
generation sequencing (Figure 1B), and organoids were histologically matched to parent 
tumors using hematoxylin and eosin, p53, and PAX8 stains (Figures 1C and S1B). TP53 
was the most common mutation in the organoids followed by various alterations in 
PIK3CA (Figure 1B), but the functional significance of these somatic alterations is unclear. 
To test for HR defects, models were treated with either 0 or 5Gy and stained for the 
HR protein RAD51 and the classic marker of DNA damage γH2AX eight hours later (Fig-
ure S2A). The number of co-localizing RAD51/γH2AX foci per nucleus was counted from 
100 nuclei for each line (Figure S2A). All models formed post-damage nuclear RAD51 foci, 
indicating no significant HR defect (Figure S2A). 
All models were analyzed for replication fork protection capacity using a DNA fiber 
assay [29] following treatment with low dose (0.1 mM) hydroxyurea (HU), a classic repli-
cation fork stalling agent (Figure S2B). In this assay, the cells are pulsed with two nucleo-
side analogs, treated with a DNA damaging agent, and the analog-labeled nascent DNA 
strands are visualized using analog-specific antibodies. The cells are assessed for protec-
tion of the second (green) track by comparing the ratio of the second (green) track to the 
first (red) [28]. If the cell can protect the forks, the ratio will be near one [28]. If there is a 
fork protection defect, the ratio will be significantly less than 1. All cells showed some fork 
degradation after HU, but only SPEC2 and 19-105 showed larger drops, suggesting a pos-
sible functional defect (Figure S2B). The significance of smaller drops was unclear, and 
given that different cells cycle at different rates, the ultimate meaning of instability ob-
served in this assay is unclear. 
3.2. TP53-Mutant UCs Show Varying Sensitivities to Classic Chemotherapies and Targeted 
DDR Agents 
Each model was tested for sensitivity to classic chemotherapeutic agents carboplatin 
and paclitaxel, and DDR agents targeting different repair pathways, including gemcita-
bine and the ATR inhibitor AZD6738 for replication fork stalling, Olaparib for HR defects, 
and the WEE1 inhibitor AZD1775 for cell cycle arrest alteration with some replication fork 
stalling. All models were treated with dose ranges for each agent to determine sensitivity 
(Figures 1D and S3). Since each line cycles at a different rate, growth rate corrected dose 
curves were generated based on mathematical normalization of the treated readouts com-
pared to a day zero readout [30]. The sensitivity, which represents the area over the 
growth rate corrected dose curve (Figure 1D), and representative growth rate corrected 
dose curves (Figure S3) are shown for each line with each agent. The greater the area over 
the growth rate corrected dose curve, the more sensitive the line is to the agent. Sensitivi-
ties to carboplatin varied as expected in these higher grade lesions which are sometimes 
unresponsive to this agent in advanced disease settings (Figure 1D). All lines demon-
strated some degree of sensitivity to paclitaxel, which causes spindle formation defects, 
suggesting possible cell cycle checkpoint issues (Figure 1D). All lines showed resistance 
to Olaparib, only showing toxicity at the highest dose (Figures 1D and S3), matching their 
capacity to form post-damage RAD51 foci (Figure S2A) and the lack of genomic alterations 
in HR genes in the organoids (Figure 1B). 
Two lines demonstrated sensitivity to the ATR inhibitor AZD6738 (20-18 and DF-85), 
indicating its potential utility in only a subset of patients (Figure 1D) [31]. All lines but 
HEC1B, AN3CA, and 19-99 demonstrated sensitivity to the classic fork stalling nucleoside 
analogue gemcitabine (Figure 1D) indicating a possible defect upon replication fork arrest 
due to inhibition of DNA synthesis undetected by DNA fiber analysis (Figure S2B). Fi-
nally, only four lines (DF-85, MFE-280, 19-105, and 20-18) showed sensitivity to the WEE1 
inhibitor AZD1775 (Figure 1D). 
Overall, the focused sensitivities to AZD1775 and the common sensitivity to 
paclitaxel suggested the potential for a cell cycle checkpoint defect in these cells. The 
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focused sensitivities to AZD6738, AZD1775, and gemcitabine also suggested that these 
tumors may have mechanistically different replication fork protection defects best de-
tected by challenging cells with each agent and then comparing them. 
 
 
Figure 1. TP53 mutant uterine carcinoma models show varying responses to classic and DNA damage repair targeted 
therapies. (A) Histologic subtype and TP53 mutation status of six cell lines and six patient-derived organoids analyzed in 
this study. (B) The most common somatic mutations or copy number alterations identified in six organoid models by 
targeted panel exome and low pass whole genome sequencing are shown here with the gene name on the left, the percent 
of organoids with the altered gene on the right, and the key to organoid line and alteration type on the bottom. (C) Hema-
toxylin and eosin stains of matched parent tumor (top left) and organoid (top right) and p53 immunohistochemistry of the 
same matched parent tumor (bottom left) and organoid (bottom right). Photos were taken at 63X and then cropped to 
focus on a single organoid or single tumor region. (D) All organoids and cell lines were tested for sensitivity to gemcita-
bine, AZD6738, Olaparib, AZD1775, carboplatin, and paclitaxel. All lines were growth rate corrected. The sensitivity (area 
over the growth rate corrected dose curve) is shown here with bars representing the average sensitivity and error bars 
representing the standard deviation between two to three replicates. 
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3.3. TP53 Mutant UCs Do Not Show Alterations in Replication Fork Protection but Some 
Harbor Cell Cycle Checkpoint Difficulties in Response to WEE1 Inhibition 
Given the sporadic replication fork and cell cycle defects in our functional assays, we 
focused on the WEE1 inhibitor AZD1775. This agent causes both cell cycle issues and rep-
lication stress and has recently shown some efficacy in a subset of TP53 mutant uterine 
serous carcinomas [13]. Therefore, we performed a deeper analysis on some of our models 
to determine what mechanistic defect caused our observed AZD1775 sensitivity in only a 
few lines and if other small molecules or combinations show increased efficacy in a larger 
subset of TP53 mutant UCs. 
We initially treated a subset of cell lines with AZD1775 and assessed upregulation of 
the replication stress DNA damage response at various timepoints over 48 hours by ex-
amining expression of key replication stress response proteins involved at stalled forks 
including early markers like phosphorylated RPA (pRPA) and γH2AX, and later markers 
like phosphorylated CHK1 (pCHK1) and phosphorylated KAP1 (pKAP1), both targets of 
the replication stress kinase ATR (Figure S4A) [32]. In all lines, the replication stress path-
way was successfully engaged, as evidenced by upregulation of pRPA, γH2AX, pCHK1, 
and pKAP1, albeit at different timepoints in each cell line likely due to varying cell cycle 
rates (Figure S4A). To ensure that no differences in replication stress response upregula-
tion were due to lack of target engagement, we assessed WEE1 inhibition by examining 
RRM2 and phosphorylated CDC2 (pCDC2) levels, which should both decrease post-treat-
ment [16,33]. In all three cell lines tested AZD1775 successfully engaged WEE1, evidenced 
by decreased phosphorylated CDC2 (Figure S4A). However, faithful degradation of 
RRM2 was not always observed (Figure S4A). These results suggested the lack of a repli-
cation stress response defect and raised the possibility of a cell cycle checkpoint as the 
critical AZD1775 target in these cells. 
Thus, we treated the same cell lines with AZD1775 and harvested for cell cycle flow 
cytometry analysis at various timepoints (Figure 2A). For each line tested, AZD1775 in-
duced some degree of G2/M arrest at 24 hours. HEC1B demonstrated the most pro-
nounced arrest suggesting that it has an intact G2/M checkpoint. In contrast, ARK1 and 
SPEC2 demonstrated smaller arrests, suggesting possible G2/M checkpoint defects. The 
different degrees of arrest may be important in understanding sensitivity to various late 
G2/M arresting agents and determining whether the cells arrested in G2 or M phase was 
important in pinpointing the location of the checkpoint defect in ARK1 and SPEC2. 
The cell lines were again treated with AZD1775 and assessed for histone H3 phos-
phorylated on serine 10 (H3pS10) to mark mitosis at various timepoints after treatment 
(Figure S4B). Each line showed an expected increase in mitotic entry marked by increased 
H3pS10 positive cells at 8 hours followed by some degree of G2 arrest marked by de-
creased H3pS10 by 24 hours (Figure S4B). 
The decreased ability of ARK1 and SPEC2 to arrest in G2/M compared to HEC1B, 
combined with no clear difference between these three cell lines in their ability to upreg-
ulate the replication stress response, hinted that the underlying functional defect in ARK1 
and SPEC2 is likely in a part of cell cycle checkpoint regulation not targeted by WEE1. The 
next question was what the mechanism of the checkpoint defect, if any, was in ARK1 and 
SPEC2 cells. 
3.4. WEE1 Inhibition Induces Upregulation of Aurora Kinase Signaling in TP53 Mutant UCs 
To determine if other cell cycle pathway defects might influence AZD1775 sensitivity 
or if there was another molecular defect in these tumors, we studied the transcriptional 
profiles of cells with varying sensitivity to AZD1775. We profiled a panel of our organoids 
including resistant (19-99), moderately sensitive (DF-85), and highly sensitive (19-105) 
lines. Each organoid line was treated with AZD1775 over a time course. Western blots 
were performed to assess WEE1 engagement (pCDC2, RRM2) and replication stress re-
sponse upregulation (pRPA, γH2AX, pKAP1, and pCHK1) in each line. As with cell lines, 
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each organoid line had successful WEE1 engagement shown by pCDC2 downregulation 
but not RRM2 alteration, and successful upregulation of the replication stress response 
shown by upregulation of pRPA, γH2AX, pKAP1, and pCHK1 at varying times after treat-
ment (Figure S4C). A vehicle and AZD1775-treated sample of each organoid line was sub-
mitted for bulk RNA sequencing analysis to assess for alterations in other pathways (Fig-
ures 2B,C and S5A,B, and Tables S1–S3). 
In each line, gene ontology (GO) overrepresentation analysis on post-AZD1775 treat-
ment upregulated genes revealed marked upregulation in G2/M related pathways (Fig-
ures 2B and S5) [25], which was most pronounced in the more responsive lines DF-85 and 
19-105. In all three lines, one of the most upregulated genes post-treatment was Aurora 
kinase A (AURKA) (Figures 2C,D and S5, and Tables S1–S3). Given the G2/M checkpoint 
deficiency after WEE1 inhibition in ARK1 and SPEC2 (Figure 2A) and the strong upregu-
lation of Aurora kinase after WEE1 inhibition in the most sensitive organoids (DF-85 and 
19-105) (Figures 2C,D and S5B), we hypothesized that some TP53 mutant UCs may have 
issues with late G2/M checkpoint function and be more reliant on Aurora kinase signaling 
at baseline or when challenged during mitosis. This Aurora kinase dependence may be a 
targetable vulnerability with the right small molecules. 
To test this, we treated our models with Alisertib (MLN8237), which inhibits Aurora 
kinase A and to a lesser extent Aurora kinase B at different concentrations (Figures 2E and 
S3) [34,35]. All of the cell lines and some of the organoids were more sensitive to Alisertib 
than AZD1775, and the remaining organoids were at least as sensitive to Alisertib as to 
AZD1775 (Figures 2E and S6A). Aurora kinase inhibitors have had success in other tumor 
types, including ovarian cancer, suggesting further exploration of the efficacy and mech-
anism of action of these agents in UC was warranted [36–39]. 
Since Alisertib targets both Aurora A and Aurora B kinases at different doses, we 
tested a subset of the cell lines for cell cycle arresting capacity and sensitivity to the Aurora 
A specific inhibitor MK5108 and the Aurora B specific inhibitor Barasertib (AZD1152) to 
determine if inhibition of one or both kinases was more effective (Figure S6B,C) [34,35]. 
Alisertib resistant HEC1B along with Alisertib sensitive ARK1, SPEC2, and AN3CA were 
treated with either MK5108 or Barasertib and harvested for cell cycle flow cytometry anal-
ysis at various timepoints post-treatment. HEC1B showed a robust G2/M arrest at 24 
hours for both MK5108 and Barasertib, reflecting its intact G2/M checkpoint (Figures 2A 
and S6B). ARK1 and AN3CA showed the strongest arrest for Barasertib with a lesser arrest 
for MK5108 suggesting difficulties in G2/M arrest after Aurora kinase A inhibition (Figure 
S6B). SPEC2 showed a stronger arrest for MK5108 than for Barasertib, suggesting issues 
with G2/M arrest after Aurora B inhibition (Figure S6B). ARK1, AN3CA, and SPEC2 
showed moderately higher sensitivity to Barasertib over MK5108, however, HEC1B, 
ARK1, and AN3CA were all more or at least equally sensitive to Alisertib compared to 
Barasertib or MK5108 (Figure S6C). Overall, the more Alisertib sensitive lines do not arrest 
as strongly in G2/M amid Aurora kinase A inhibition and are less sensitive to Aurora ki-
nase A inhibition alone. Taken together, these results suggest something unique about the 
dual Aurora kinase A/B inhibitory properties of Alisertib in UCs. 
We next tested if Alisertib exerts its cytotoxicity through apoptosis in UC, as occurs 
in other tumor types, despite the TP53 mutations in our UC cells (Figure 1A) [34,35]. In 
this regard, we found that WEE1 inhibitor sensitive lines DF-85 and 19-105 upregulated 
the p53 target p21 (CDKN1A) after AZD1775 treatment (Figure 2F). p21 has a role in in-
ducing and protecting against apoptosis in p53-dependent and independent manners, 
suggesting that these TP53 mutant UCs may undergo apoptosis in response to cell cycle 
challenges such as WEE1 or Aurora kinase inhibition [40,41]. Thus, we assessed a subset 
of our cell lines for apoptosis by examining levels of the apoptosis marker cleaved PARP 
after Alisertib treatment (Figure 2G). HEC1B, SPEC2, ARK1, and AN3CA demonstrated 
increased cleaved PARP after Alisertib treatment (Figure 2G) suggesting that even in these 
TP53 mutant cells, apoptosis was induced. 
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Overall, these results suggested that later G2/M arrest at the time of spindle for-
mation targeted by Aurora kinase inhibition may be a more effective therapeutic target 
than WEE1 inhibition in TP53 mutant UCs. We next questioned how these agents induced 
apoptosis in TP53 mutant cells. 
 
  




Figure 2. WEE1 inhibition induces significant AURKA upregulation in AZD1775 sensitive uterine carcinoma models, 
unmasking a strong vulnerability of TP53 mutant uterine carcinomas to Aurora kinase inhibition. (A) BrdU/propidium 
iodide cell cycle flow cytometry analysis was performed on a subset of cell lines at various timepoints after vehicle (con) 
or 0.5 uM AZD1775 (1775) treatment. The bars show different phases of the cell cycle (white G2-M, gray S, black G0-G1), 
and error bars represent standard deviation between two to three replicates. (B) Bulk RNA sequencing analysis of the 
treated organoids compared to the untreated set revealed significant enrichment for genes related to G2/M after GO 
overrepresentation analysis. In the graph, GO terms are listed on the Y-axis, circles represent the number of genes in the 
GO term group, and the X-axis represents increasing significance. (C,D) One of the most significantly upregulated genes 
in each organoid line post-AZD1775 treatment was AURKA, as shown in the volcano plot for DF-85 treated vs. vehicle in 
C and the log2 fold change bar graph in each line in D. For the volcano plot in C, p-values of increasing significance are 
shown on the y-axis and increasing log2 fold change is shown on the X-axis. A black circle indicates genes with non-
significant (NS) change, and a red circle indicates significantly upregulated genes. For the bar graph in D, p-values were 
generated using an FDR-adjusted Wald test comparing expression in treatment versus control. * p < 0.05. (E) All cell lines 
and organoids were tested for sensitivity to the dual Aurora A/B kinase inhibitor Alisertib. Each sensitivity curve was run 
twice, and all lines were growth rate corrected. The sensitivity (area over the growth rate corrected dose curve) is shown 
here with bars representing the average sensitivity and error bars representing the standard deviation between two repli-
cates. (F) The log2 fold change of AZD1775 treatment compared to control bar graph for CDKN1A expression in each line 
is shown here. p-values were generated using an FDR-adjusted Wald test comparing expression in treatment versus con-
trol. * p < 0.05 and NS = not significant. (G) Four of the cell lines were treated with 0.25 uM Alisertib for 24 hours and 
harvested either at the start of the time course (0 hr) or at varying points over the time course. Western blots were per-
formed on lysates from the cell lines to analyze for the apoptosis marker cleaved PARP and for Vinculin as a control. 
3.5. Alisertib Induces Apoptosis in TP53 Mutant UCs by Targeting Aurora Kinase–LKB1–p53–
AKT Interlinked Signaling in a Mutant p53 Dependent Mechanism 
Aurora kinases link to apoptosis signaling pathways regulated by the LKB1 ser-
ine/threonine kinase, including p53 and PI3K/AKT (Figure 3A) [18,35]. LKB1 is a tumor 
suppressor involved in many cellular functions surrounding cell cycle control, energy, 
metabolism, and polarity which it regulates through AMPK/mTOR signaling [18,42]. In 
one pathway LKB1 regulates p53 and p21 cell cycle and apoptosis control, and in another 
linked pathway LKB1 regulates PI3K/AKT mediated proliferation and anti-apoptotic sig-
naling (Figure 3A) [18]. The Alisertib target Aurora kinase A phosphorylates and regu-
lates LKB1 [35,43], and also phosphorylates and activates p53 [34,35] (Figure 3A). Given 
the connections between Aurora kinase A, LKB1, p53, and AKT, our question was if 
Alisertib induced apoptosis through inhibition somewhere within the web of LKB1 sig-
naling despite the genomic alterations in TP53 and the PI3K/AKT family in most of our 
models (Figures 1A,B) [20–23]. 
To test this, we investigated potential synthetic lethality with Aurora kinase inhibi-
tion and LKB1 loss of function. In both the G2/M checkpoint defective/Alisertib sensitive 
ARK1 and the G2/M checkpoint proficient/Alisertib resistant HEC1B lines, LKB1 deple-
tion increased Alisertib sensitivity (Figure 3B). Additionally, p21, which is not expressed 
in HEC1B [44], was upregulated after LKB1 inhibition in ARK1 cells serving as a control, 
Cancers 2021, 13, 2195 10 of 23 
 
 
since LKB1 normally regulates p21 (Figure 3B). This result indicated that Alisertib-in-
duced apoptosis occurred either through dysregulation or inhibition of the p53 or AKT-
mediated arms of the LKB1 pathway, or both. Thus, we next asked which LKB1 pathway 
Alisertib targeted. 
We initially hoped to test whether p53 was involved in the Alisertib response. How-
ever, all of our organoids and cell lines are p53 mutant (Figure 1A). Thus, we first had to 
address whether the mutant p53 was expressed and active in our UC models. We exam-
ined p53 expression in two of the lines, HEC1B and ARK1, after treatment with control or 
p53 specific siRNAs (Figure 3C) to determine if the mutant p53 was expressed and which 
isoforms were relevant. We found two specific and shared isoforms with the higher iso-
form expressed near 53kDa as expected for full length p53, and both isoforms were repro-
ducibly depleted by the TP53 specific siRNAs (Figure 3C). 
Given this, our next question was whether or not the expressed mutant p53 had any 
baseline function. To test for an inhibitory function, we treated a subset of our cell lines 
and organoids with Nutlin, which causes p53 activation by inhibiting the p53 regulatory 
partner MDM2 [45,46]. Cells with functional p53 at baseline are highly sensitive to Nutlin 
[45,46]. As controls, we tested U2OS cells and human mammary epithelial cells (HMECs), 
both known to be TP53 wild type. We found that all our tested models are Nutlin resistant 
compared to the U2OS and HMEC controls (Figure 3D), suggesting the mutant p53 did 
not have an inhibitory baseline function. 
To assess if the mutant p53 had a protective baseline function, we depleted p53 with 
multiple gene specific siRNAs and assessed for apoptotic death (Figure 3E). We found 
that in ARK1 but not in HEC1B, p53 depletion leads to increased apoptosis (Figure 3E). 
Since ARK1 appears to have a deficient G2/M checkpoint while HEC1B is proficient, we 
hypothesized that perhaps the mutant p53 serves a protective baseline function allowing 
ARK1 cells to progress through mitosis with some degree of mitotic defects. When the 
mitotic defects are enhanced at the right point in mitosis, such as with the spindle defects 
induced by Alisertib, then this mutant p53 may serve a different function. 
Thus, we next tested if mutant p53 has a role in the Alisertib response. First, we stud-
ied p53 expression in SPEC2, AN3CA, HEC1B, and ARK1 after Alisertib treatment to see 
if p53 was upregulated in response to treatment. We found the full length 53kDa molecu-
lar weight band of mutant p53 upregulated in all lines at various timepoints post-treat-
ment (Figure 3F). In ARK1, AN3CA, and SPEC2, this upregulated band appeared as a 
doublet or a smear, suggesting that the mutant p53 was undergoing some form of post-
translational modification in response to Alisertib. Indeed, p53 is phosphorylated during 
cell cycle arrest or other states of cellular stress releasing it from control by its regulatory 
partner MDM2 [7,8,45,46]. Thus, we tested for phosphorylation of mutant p53 after treat-
ment. We found that the post-Alisertib upregulated p53 in HEC1B and ARK1 is phosphor-
ylated on Serine 15, suggesting it is active (Figure 3G). The next question was if mutant 
p53 has a role in the apoptotic response to Alisertib. 
To test this, we tried multiple methods of altering p53 function in combination with 
Alisertib. First we overexpressed a dominant negative form of p53 (p53DD) in HEC1Bs, 
which should bind and block the function of any p53, to determine whether losing p53 
function altered Alisertib sensitivity (Figure 3H) [47]. This dominant negative p53 was 
heavily expressed at the same molecular weight of 53 kDa as the endogenous p53 (Figure 
3C,3F,3G) but caused only a small and not statistically significant decrease in HEC1B 
Alisertib sensitivity, suggesting that p53 function may be needed to enhance the Alisertib 
response (Figure 3H). Thus, we next asked whether activating the mutant p53 by releasing 
it from MDM2 with Nutlin might increase sensitivity to Alisertib (Figure 3I). Indeed, treat-
ment of HEC1B or ARK1 cells with an Alisertib dose curve combined with a constant dose 
of Nutlin compared to vehicle increased the sensitivity of these cells to Alisertib (Figure 
3I). Taken together, these data indicate that mutant p53 and thus the p53 arm of the LKB1 
pathway is not inhibited by Alisertib, rather it actively influences Alisertib-induced cell 
death (Figure 3I). The next question was whether the p53 and LKB1 target p21 had any 
Cancers 2021, 13, 2195 11 of 23 
 
 
role in Alisertib response, given its upregulation in response to other cell cycle altering 
drugs like WEE1 inhibitors (Figures 2F and 3A). 
To test for a p21 role in response to Alisertib in TP53 mutant UCs we treated ARK1 
with Alisertib as HEC1B does not express p21 [44], harvested at various timepoints, and 
found p21 upregulated post-treatment (Figure 3J). We next asked whether p21 was pro-
tective or pro-apoptotic by depleting p21 in ARK1 cells and studying Alisertib response 
after p21 loss (Figure 3K). Upon p21 depletion, ARK1 cells showed a modest increase in 
Alisertib sensitivity, suggesting either a limited role or possibly a small anti-apoptotic role 
for p21 during Alisertib induced G2/M arrest (Figure 3K). 
Our next question was whether or not the AKT arm of LKB1 signaling was inhibited 
by or is actively involved in the Alisertib response, especially since there are mutations in 
members of this pathway in most of our models (Figure 1B) [20,23]. LKB1 and AKT acti-
vation require phosphorylation [18,48], and we hypothesized that if Alisertib-induced 
death relies upon LKB1–AKT signaling, there may be differences in the activation of this 
pathway in Alisertib-resistant versus sensitive cells. Accordingly, we assessed phosphor-
ylated LKB1 or AKT upregulation after Alisertib treatment in multiple UC lines (Figure 
4A). In Alisertib resistant HEC1B and sensitive SPEC2 and ARK1, phosphorylated LKB1 
and AKT reproducibly increased at various timepoints between three and 24 hours after 
Alisertib treatment. In addition, AKT was phosphorylated to a lesser extent at baseline in 
all three lines (Figure 4A), reflecting its potential baseline activation by alterations in the 
pathway which are common in UC [20,23]. Taken together, this indicated that LKB1–AKT 
signaling was already active at baseline possibly serving some protective function, upreg-
ulated in response to Alisertib, and intact to the point of AKT phosphorylation in all UC 
lines tested. Our next question was whether the upregulated AKT was active in the cellu-
lar response to Alisertib. 
To address this, we treated ARK1 and HEC1B with either a dose curve of Alisertib, 
the pan-AKT inhibitor Ipatasertib, or Alisertib combined with Ipatasertib, hypothesizing 
that if AKT plays an active role in the cellular response to Alisertib, then its inhibition 
should alter Alisertib sensitivity (Figure 4B) [48,49]. In ARK1 and HEC1B, cells showed 
no response to Ipatasertib as a single agent (Figure 4B). The Alisertib+Ipatasertib combi-
nation induced only small changes compared to Alisertib alone. In Alisertib resistant 
HEC1B, the combination of Alisertib with Ipatasertib caused a small but significant in-
crease in sensitivity over Alisertib (Figure 4B). In contrast, in Alisertib sensitive ARK1 
cells, the combination caused a modest but significant decrease in sensitivity to Alisertib. 
These results suggest that the AKT arm of the LKB1 signaling pathway is a major target 
of Alisertib but is incompletely downregulated by it, as shown by the minute changes 
induced by AKT inhibition in combination with Alisertib over Alisertib alone. The fact 
that the pathway is a target suggests it plays a role in protecting G2/M checkpoint deficient 
cells at baseline, as these cells undergo apoptosis when the pathway is inhibited by 
Alisertib. Further inhibiting the pathway, at least with AKT inhibition, did not strongly 
enhance Alisertib induced cell death, suggesting that Alisertib inhibits more of the LKB1–
AKT signaling web than just AKT. 




Figure 3. Aurora kinase inhibitor cytotoxicity is mediated in part through the function of mutant p53 and LKB1 signal-
ing. (A) A cartoon demonstrating how Aurora kinase is linked to both the p53/p21 and PI3K/AKT arms of LKB1 kinase 
signaling. (B) ARK1 and HEC1B cells were transfected with either a control siRNA (si-con) or one of two LKB1 specific 
siRNAs (si-LKB1-1 or si-LKB1-6) and then treated with a dose range of Alisertib. Western blots showing LKB1 depletion, 
and p21 upregulation in the case of ARK1, are shown on the left. Two bands were detected, and the top band indicated 
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by an arrow represents the phosphorylated form. Sensitivities (area over the growth rate corrected dose curve) are shown 
on the right for each cell line with each siRNA. Bars represent the average of three replicates, and error bars represent 
standard error of the mean. p-values were calculated using a paired t-test. * p < 0.05. (C) Western blots demonstrating p53 
depletion in HEC1B and ARK1 with two p53 specific siRNAs (sip53-5 and sip53-7) compared to a control. Two isoforms 
of p53 are detected, but the top isoform running at 53kDa indicated by an arrow here represents the full length p53 chang-
ing with treatment in the remaining figures. (D) A representative subset of TP53 mutant uterine cancer cell lines and 
organoids along with TP53 wild-type human mammary epithelial cells (HMEC) and U2OS cells were treated with a dose 
range of Nutlin and analyzed for survival. All lines were growth rate corrected, and the sensitivity (area over the growth 
rate corrected dose curve) is shown here for each line. The bars represent the average sensitivity, and error bars represent 
the standard deviation for two replicates. (E) HEC1B and ARK1 were transfected with two separate p53-specific siRNAs 
compared to control (si-con) and analyzed for apoptotic dead cells 72 hours later. The average percentage of apoptotic 
dead cells is shown here with error bars representing the standard error of the mean and p values generated using a t-test 
for three replicates. * p < 0.05 and NS = not significant. (F) Cell lines were treated with 0.25 uM Alisertib (Alis) over a 24 
hour period compared to a 0 hr control (con), and lysates were prepared at various timepoints and blotted for full length 
p53 with vinculin as a loading control. (G) Cell lines were treated with 0.25 uM Alisertib (Alis) over a 24 hour period 
compared to a 0 hr control (con), and lysates were prepared at various timepoints and stained for p53 phosphorylated on 
serine 15 (p53 pS15). Loading controls included vinculin, GAPDH, and p53. An arrow indicates the 53kDa molecular 
weight band that represents full length p53 and is phosphorylated and changing with treatment. (H) HEC1Bs were stably 
transfected with empty vector or a dominant negative p53 (p53DD) and then treated with a dose range of Alisertib. A 
western blot for p53 is shown on the left, showing the overexpressed protein correctly running at 53kDa, and the sensitivity 
(area over the growth rate corrected dose curve) for Alisertib is shown on the right. Bars represent the average of three 
replicates, and error bars represent the standard error of the mean. p-values were generated using a t-test comparing 
vector to p53DD. NS = not significant. (I) ARK1 and HEC1B cells were treated with a dose range of Alisertib in combination 
with either a fixed dose of DMSO or a fixed dose of 5 uM Nutlin. Representative growth rate corrected dose curves are 
shown on the left with a key to treatments/cell lines on the bottom, and the sensitivity (area over the growth rate corrected 
dose curve) for both lines is shown on the right. Bars represent the average of three replicates, and error bars represent 
standard error of the mean. p-values were calculated using a paired t-test comparing vehicle-Alisertib to Nutlin-Alisertib. 
* p < 0.05. (J) ARK1 cells were tested for p21 upregulation after 0.25 uM Alisertib (Alis) treatment over a 24 hour period. 
An untreated control (con) was harvested at 0 hr. p21 expression was studied by western blot over the time course with 
vinculin as a loading control. (K) ARK1 cells were transfected with either a control siRNA (si-con) or one of two p21 
specific siRNAs (si-p21-1 or si-p21-4) and then treated with a dose curve of Alisertib. On the left is a western blot for p21 
in the control or p21 depleted cells with vinculin as a loading control. On the right is the sensitivity (area over the growth 
rate corrected dose curve) for the growth rate corrected dose curves of the cells. Four replicates were performed with each 
siRNA. Error bars represent the standard error of the mean, and p-values were generated using a t-test comparing si-con 
to gene specific siRNAs. * p < 0.05. 
Taken together, these data suggested that (1) both Alisertib sensitive (ARK1 and 
SPEC2) and resistant (HEC1B) cells rely upon LKB1–p53–AKT interconnected signaling, 
and (2) Alisertib engages the p53 and AKT arms of the LKB1 pathway simultaneously, 
likely utilizing the p53 arm to induce cell death and blocking the protective AKT arm. 
However, Alisertib sensitivity requires an additional functional defect as evidenced by 
the resistance of HEC1B when compared to ARK1 or SPEC2. Consequently, our next ques-
tion was what the additional defect mediating Alisertib sensitivity was and how Alisertib 
resistance in cells lacking such a defect, like HEC1B, can be overcome. 
3.6. Combining Aurora Kinase and WEE1 Inhibitors Overcomes Aurora Kinase Inhibitor 
Resistance 
HEC1B demonstrated the strongest cell cycle checkpoint arrest in response to WEE1 
or Aurora kinase inhibition (Figures 2A and S6B), and we hypothesized that their Alisertib 
resistance was due to this functional G2/M checkpoint. Alisertib induces mitotic spindle 
defects, halting mitosis at metaphase [50]. In head and neck cancers, regardless of TP53 
mutation status, combining WEE1 and Aurora kinase inhibitors leads to enhanced cell 
death over either agent alone because WEE1 inhibition triggers mitotic progression in cells 
with Alisertib-induced spindle defects [38]. We speculated that major spindle defects in-
duced by Aurora kinase inhibition combined with both G2/M checkpoint defects and 
dysregulation of the Aurora kinase-regulated LKB1–p53–AKT pathway may allow for ef-
ficient Alisertib killing of most TP53 mutant UC cells. In those with intact G2/M 
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checkpoints, like HEC1B, WEE1 inhibitor-induced mitotic progression is needed in tan-
dem with Aurora kinase inhibitor-induced spindle defects for more efficient cell death. 
To test this, we treated HEC1B, ARK1, SPEC2, and AN3CA with either Alisertib, 
AZD1775, or Alisertib+AZD1775 and assessed cell survival (Figure 4C). In the Alisertib 
sensitive lines AN3CA, ARK1, and SPEC2, there was a minor but statistically significant 
increase in sensitivity for the combination over Alisertib (Figure 4C). In contrast, in 
Alisertib resistant HEC1B cells, the combination of AZD1775 with Alisertib led to a large 
and statistically significant increase in sensitivity compared to either agent alone, and  
also larger than combining either an MDM2 or an AKT inhibitor with Alisertib (Figures 
3I and 4B,C). 
 
Figure 4. Combining Aurora kinase and WEE1 kinase inhibitors overcomes Aurora kinase inhibitor resistance. (A) Cell 
lines were treated with 0.25 uM Alisertib (Alis) over a 24 hour period compared to a 0 hr untreated control (con), and 
lysates were prepared from cells harvested at 3, 8, and 24 hours post-treatment and analyzed for LKB1 and AKT expression 
and modification (AKT phosphorylated on Serine 473 (pAKT Ser) or Threonine 308 (pAKT Thr) and LKB1 phosphorylated 
on Serine 428 (pLKB1)). In the LKB1 and pLKB1 blots, an arrow indicates the higher molecular weight phosphorylated 
band. (B) An Alisertib resistant (HEC1B) and sensitive (ARK1) cell line was treated with either Alisertib, Ipatasertib, or a 
combination of Alisertib and Ipatasertib (Ipat + Alis). Representative growth rate corrected dose curves are shown for each 
line on the left, and sensitivity (area over the growth rate corrected dose curve) is shown on the right for each line with 
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each treatment. Bars represent the average of four replicates, and error bars represent the standard error of the mean. p-
values were calculated using both a two-way ANOVA test and a paired t-test comparing different single treatments to the 
combination or each other. * p < 0.05 for both tests. Comparisons are indicated by a horizontal line over the bars for the 
treatments being compared (Alisertib vs. Ipatasertib, Alisertib vs. Ipatasertib+Alisertib, and Ipatasertib vs. Ipa-
tasertib+Alisertib). (C) An Alisertib resistant (HEC1B) and three sensitive (ARK1, SPEC2, AN3CA) cell lines were treated 
with either Alisertib, AZD1775, or a combination of Alisertib and AZD1775. Representative growth rate corrected dose 
curves are shown for each line on the left, and sensitivity (area over the growth rate corrected dose curve) is shown on the 
right for each line with each treatment. Bars represent the average of three to five replicates, and error bars represent 
standard error of the mean. p-values were calculated using both a two-way ANOVA test and a paired t-test comparing 
different single treatments to the combination or each other. * p < 0.05 for both tests. Comparisons are indicated by a 
horizontal line over the bars for the treatments being compared (Alisertib vs. AZD1775, Alisertib vs. AZD1775+Alisertib, 
and AZD1775 vs. AZD1775+ Alisertib). 
This increased sensitivity in the resistant HEC1B line and to a smaller extent in the 
three Alisertib sensitive lines could be due to (1) the combination of DNA damage induced 
by AZD1775 with mitotic irregularities induced by Alisertib, or (2) the combination of 
progression into mitosis induced by AZD1775 with mitotic irregularities induced by 
Alisertib. To determine which occurred, all four lines were treated with vehicle, Alisertib, 
AZD1775, or Alisertib+AZD1775 and assessed for replication stress response and cell cy-
cle proteins by western blot (Figure S7A). All lines tested showed some upregulation of 
the replication stress response proteins pRPA, γH2AX, pKAP1, and pCHK1 in response 
to AZD1775 alone or in combination with Alisertib, indicating no replication stress re-
sponse defects (Figure S7A). AZD1775 clearly engaged WEE1, evidenced by decreased 
pCDC2 expression over time (Figure S7A). In Alisertib resistant HEC1B, AZD1775 alone 
or in combination with Alisertib induced progression into mitosis evidenced by strong 
H3pS10 expression (Figure S7A). Comparatively, Alisertib sensitive AN3CA and ARK1 
had H3pS10 expression and progression to mitosis with AZD1775 alone, but they had less 
H3pS10 expression and possibly less progression through mitosis in the setting of the 
combination (Figure S7A). However, these lines also showed less G2/M arrest with 
AZD1775, MK5108, and Barasertib alone compared to HEC1B (Figures 2A and S6B). 
SPEC2 demonstrated strong H3pS10 with either single agent or the combination at 24 
hours, which was expected given its lack of arrest with all agents tested thus far (Figures 
2A and S6B). Thus, we hypothesized that HEC1B maintains a strong G2/M checkpoint 
compared to the other cell lines, and the double Aurora and WEE1 kinase block is needed 
to advance mitosis amid mitotic/spindle abnormalities, leading to cell death. 
To test this, AN3CA, ARK1, SPEC2, and HEC1B were treated with vehicle, Alisertib, 
AZD1775, or Alisertib+AZD1775, and cell cycle progression was assessed by flow cytom-
etry analysis. HEC1B, ARK1, and AN3CA all showed significant G2/M arrest with both 
Alisertib or Alisertib combined with AZD1775 while SPEC2 did not, reflecting its inability 
to arrest after any challenge to G2 or M progression (Figures 2A, 5A and S6B). For HEC1B, 
ARK1, and AN3CA, this indicated some form of arrest either in G2 or potentially mitosis. 
To better assess mitotic figure formation, mitotic catastrophe, or apoptotic blebbing 
post-treatment, AN3CA, ARK1, SPEC2, and HEC1B were treated with vehicle, Alisertib, 
AZD1775, or Alisertib+AZD1775 and stained for H3pS10 to mark mitosis and tubulin to 
mark mitotic spindles 24 hours after treatment. Cells with normal or Alisertib-altered mi-
totic figures, mitotic catastrophes, and apoptotic blebs were counted in each setting (Fig-
ures 5B–D). Alisertib altered mitotic figures demonstrated distinct spindle formations and 
never revealed anaphase forms (Figure 5D). Overall, the result for each treatment fit what 
was expected for the treatment and checkpoint function background. 
In the vehicle treated group, the percentage of mitotic cells was uniform near 5% for 
all four cell lines (Figure 5C). For AZD1775, we showed that treatment at the 0.5 uM con-
centration used here pushes cells into mitosis at approximately 8 hours post-treatment 
(Figure S4B), so at this 24 hour timepoint, we would expect to see the aftermath of that 
push. Indeed, increased mitotic catastrophes were present in all four cell lines, and 
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increased apoptotic blebbing cells were present in HEC1B, AN3CA, and ARK1 after single 
agent AZD1775 (Figure 5C). 
For Alisertib, we expect to see significantly more mitotic figures and potentially some 
level of apoptosis based on flow cytometry and western analysis (Figures 2G and 5A). All 
four cell lines showed some level of apoptotic blebbing cells and the most mitotic figures 
with Alisertib compared to other treatments (Figure 5C). Fitting with the Alisertib-sensi-
tive phenotype, the apoptotic blebbing cells were the highest after Alisertib alone for 
ARK1, SPEC2, and AN3CA (Figure 5C). 
Finally, for the Alisertib+AZD1775 combination, we saw some percentage of apopto-
sis, mitotic figures, and catastrophes in all four cell lines (Figure 5C). Knowing that 
AZD1775 induces a push into mitosis around 8 hours of treatment and that Alisertib in-
duces increased numbers of altered mitotic figures simultaneous to this, by 24 hours we 
expect to see the aftermath of a push through mitosis of a malformed mitotic figure. In 
cells with dysfunctional G2/M checkpoints like ARK1, SPEC2, and AN3CA, we still ob-
served some mitotic figures, likely reflecting the dysfunctional G2/M checkpoint regard-
less of treatment (Figure 5C). In addition, apoptotic blebs were present in ARK1 and 
AN3CA likely due to their known Alisertib sensitivity and the lack of an effect of 
AZD1775 on their already defective checkpoints (Figure 5C). In contrast, for HEC1B there 
were less than 1% mitotic cells and only apoptosis with the combination (Figure 5C), fit-
ting with the hypothesis that the AZD1775 block of the checkpoint in these cells pushes 
the Alisertib-induced abnormal mitotic figures through mitosis when they otherwise 
would have arrested, and then these abnormal mitotic cells enter apoptosis. Since 
blebbing represents only one phase of apoptosis, we next wanted to confirm our findings 
with additional apoptosis markers, especially in SPEC2 where apoptotic cells were not as 
easily observed. 
To demonstrate the increased apoptosis induced by the combination in HEC1B cells 
beyond just what was visible by eye, HEC1B were treated with vehicle, Alisertib, 
AZD1775, or Alisertib+AZD1775 and assessed for increased apoptosis by flow cytometry 
and cleaved PARP western blot 24 hours after treatment. The combination was the only 
treatment to induce significant apoptosis over control by flow cytometry in HEC1B (Fig-
ure 5E), and at 24 hours, the combination had the highest level of cleaved PARP, albeit 
both single drugs and the combination induced cleaved PARP as well at earlier timepoints 
(Figure 5F). The same flow cytometry was performed for ARK1, SPEC2, and AN3CA (Fig-
ure S7B). SPEC2 showed significant apoptosis only with Alisertib fitting with the previous 
counts (Figures S7B and 5C), ARK1 with both AZD1775 and Alisertib, and AN3CA most 
strongly with the combination but also with Alisertib (Figure S7B). A similar western blot 
time course for ARK1 revealed the strongest cleaved PARP at 24 hours for the combina-
tion similar to HEC1B (Figure S7C). Taken together, these data support that combined 
WEE1–Aurora kinase inhibition is needed to overcome intact G2/M checkpoints and in-








Figure 5. Combining Aurora kinase and WEE1 inhibitors causes increased apoptotic death in Aurora kinase inhibitor 
resistant cells. (A) Cell lines were treated with vehicle (control) or either 0.25 uM Alisertib, 0.5 uM AZD1775 (1775), or a 
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combination of Alisertib+AZD1775 and harvested at 3, 8, and 24 hours post treatment for BrdU cell cycle flow cytometry 
analysis. Bar graphs showing the percentage of cells in G0-G1 (Black), S (Gray), and G2/M (White) at each timepoint after 
each treatment are shown here. Error bars represent standard deviation between two to three replicates. (B,C) Cell lines 
were treated with vehicle (DMSO) or either 0.25 uM Alisertib, 0.5 uM AZD1775 (1775), or a combination of Alisertib and 
AZD1775 and harvested at 24 hours for immunofluorescence analysis of mitosis and apoptosis. Cells were stained for 
H3pS10 to mark mitosis, tubulin to mark spindles, and DAPI to mark nuclei. Representative images of each cell type or 
phase counted are shown on the left in B, and bar graphs of the counts are shown on the right in C. For the images, photos 
were taken at 63X and then cropped to focus on a group of cells. Normal or Alisertib altered mitotic figures (blue), mitotic 
catastrophes (yellow) and apoptotic blebbing cells (black) were counted per at least 100 nuclei for each treatment. Bars 
represent averages of three replicates, and error bars represent standard deviation. (D) A representative altered mitotic 
figure with abnormal spindles is shown here for Alisertib treated HEC1B cells at 24 hours, which were counted in C. For 
the image, a photo was taken at 100X and then cropped to focus on the single mitotic figure. (E) HEC1B cells were treated 
with vehicle (DMSO) or either 0.25 uM Alisertib, 0.5 uM AZD1775, or a combination of Alisertib and AZD1775 and har-
vested 24 hours post-treatment for apoptosis flow using Apotracker. The percentage of dead apoptotic cells for each treat-
ment is shown for four replicates. Bars represent averages of four replicates, and error bars represent standard error of the 
mean. t-tests were used to calculate p-values, and a * above a bar indicates significance compared to the DMSO control. * 
p < 0.05. (F) HEC1B were treated with nothing (untreated) or either 0.25 uM Alisertib, 0.5 uM AZD1775 (1775), or a com-
bination of Alisertib+AZD1775, harvested at various times post-treatment, and analyzed by western blot for cleaved PARP 
and tubulin as a control. 
 
Figure 6. Aurora kinase signaling is an effective target in TP53 uterine carcinomas with G2/M checkpoint dysfunction. 
Illustration of Alisertib effects on cells with or without functional G2/M checkpoints and how the addition of AZD1775 
helps increase Alisertib efficacy. 
4. Discussion 
The functional and therapeutic significance of TP53 mutations in UC has not been 
well defined. Here, using a panel of TP53 mutant UC cell lines and PDOs, we determined 
the key functional defect in these tumors is not in the replication stress DNA damage 
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response but rather in mitosis and G2/M cell cycle checkpoints. This defect reveals a 
unique dependency in many of these tumors on Aurora kinase–LKB1–p53–AKT mediated 
cell cycle checkpoint control, often altered in UCs through TP53, PIK3CA, or AKT1 muta-
tions [18,42]. This dependency reveals a novel mechanism for TP53 mutant UC cell sur-
vival and two new therapies to target this mechanism, including Aurora kinase inhibitors 
either alone or in combination with WEE1 inhibitors. 
Key to discovering this mechanistic defect was functional assessment of G2/M cell 
cycle checkpoints across a panel of TP53 mutant models. Our data indicate that at baseline, 
many TP53 mutant UC cells, represented here by ARK1, AN3CA, and SPEC2, harbor dif-
ficulties with G2/M checkpoints and mitosis yet survive due to a combination of mutant 
p53 protein function and upregulation of Aurora kinase–LKB1–p53–AKT signaling (Fig-
ures 2–6). Alisertib treatment generates increased altered mitotic figures in these already 
G2/M checkpoint defective cells (Figure 5C,D). Simultaneously, it alters the LKB1–p53–
AKT signaling they normally rely upon to progress through mitosis with these defects, in 
tandem leading to apoptotic cell death (Figure 6). In contrast, in other TP53 mutant UC 
cells, represented by HEC1B, there is an intact G2/M checkpoint that handles mitotic ir-
regularities appropriately at baseline regardless of LKB1–AKT pathway status (Figures 
2A, 5A,C, 6, and S6B). In the setting of Aurora kinase inhibition in these cells, altered mi-
toses may form, but the intact checkpoint allows the cells to repair these issues without as 
much baseline reliance on AKT signaling (Figures 5A,C and 6). We show that combining 
WEE1 and Aurora kinase inhibition in these cells allows for altered mitoses to form and 
forces them to progress in mitosis, leading to apoptotic cell death (Figures 4C, 5, and 6). 
This mechanism-driven combination may be effective not just in uterine but potentially 
in TP53 mutant ovarian cancer as well, where Alisertib has been tested as a single agent 
or in combination with paclitaxel with some success [39]. Understanding the functional 
defects (e.g. G2/M checkpoint) or essential drivers (e.g. AKT/PI3K) in every unique tumor 
to identify the best combinations will be critical in further studies. 
In elucidating this mechanism, we have defined an unexpected fundamental role for 
the commonly mutated PI3K/AKT pathway in UC [4]. The pathway has roles in many 
major cellular processes including control of cell growth, apoptosis, the cell cycle, and 
cellular polarity amongst others and was thought to drive growth and survival in these 
cells [18]. However, we show that genomic alterations in the PI3K/AKT signaling pathway 
leading to constitutive activation, such as those in our models (Figure 1B) [20,23], may 
combine with G2/M checkpoint defects to help tumor cells survive traversing the cell cycle 
despite issues with irregular mitoses, highlighting this pathway as a critical dependency 
and major target for an unexpected reason (Figures 4A,B and 6). 
In addition, we demonstrate an unexpected role for the mutant p53 present in these 
tumors. We show that mutant p53 has a protective role at baseline in G2/M checkpoint 
deficient ARK1 cells, is upregulated and phosphorylated in response to Alisertib treat-
ment, and that increasing mutant p53 activity through Nutlin induced release from 
MDM2 control enhances Alisertib toxicity (Figure 3). Taken together, these results suggest  
mutant p53 may still participate in cell cycle control or apoptosis amid cellular stress at 
baseline and due to treatment. This raises the possibility that activating mutant p53 along-
side small molecules targeting other molecular defects may be worth exploring in UC 
[45,46]. 
5. Conclusions 
Overall, these results reveal  many TP53 mutant UCs have difficulties traversing mi-
tosis and depend upon both late G2/M checkpoint defects and Aurora kinase–LKB1–
AKT–p53 interconnected signaling to survive, making them highly sensitive to Aurora 
kinase inhibition. These defects are not readily detected by genomic sequencing or histo-
logical analyses; rather, functional testing of key cell cycle checkpoints after challenges 
with different small molecules is necessary to detect the defect and predict therapy re-
sponse. In a clinical setting, this may be accomplished by assessing checkpoint efficacy 
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after different therapeutic challenges in PDOs as a biomarker for response to each respec-
tive therapy. Further work will be needed in PDOs across all UC histology types (clear 
cell, carcinosarcoma, etc.) with all types of TP53 mutations (deletion, point mutation, etc.) 
to validate this possible biomarker. For those TP53 mutant UCs with intact G2/M check-
points, combining WEE1 and Aurora kinase inhibitors is an effective strategy. These ther-
apies represent relevant mechanism driven strategies for patients with these difficult to 
treat tumors who have limited options beyond standard chemotherapy and surgery. 
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